Collegium Pharmaceutical, Inc. Financing Cash Flow
Collegium Pharmaceutical, Inc. (COLL) reported Financing Cash Flow of $270.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $292.09M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$21.34M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$21.82M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$14.82M, a 109.94% decline year-over-year.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$110.25M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$60.60M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$140.18M, a 132.10% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $436.72M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $292.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $270.75M 10-Q · filed 2026-08-06 | $248.93M derived: sum of 3 quarters · filed 2026-08-06 | $234.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$21.34M 10-Q · filed 2026-05-07 | -$43.16M derived: sum of 2 quarters · filed 2026-05-07 | -$57.98M derived: sum of 3 quarters · filed 2026-05-07 | -$106.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$21.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$36.64M derived: sum of 2 quarters · filed 2026-02-26 | -$85.01M derived: sum of 3 quarters · filed 2026-08-06 | -$110.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$14.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$63.19M derived: sum of 2 quarters · filed 2026-08-06 | -$88.42M 10-Q · filed 2025-11-06 | -$129.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$48.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$73.61M 10-Q · filed 2026-08-06 | -$114.88M derived: sum of 3 quarters · filed 2026-08-06 | $34.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$25.24M 10-Q · filed 2026-05-07 | -$66.51M derived: sum of 2 quarters · filed 2026-05-07 | $82.52M derived: sum of 3 quarters · filed 2026-05-07 | -$31.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$41.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $107.75M derived: sum of 2 quarters · filed 2026-02-26 | -$6.46M derived: sum of 3 quarters · filed 2026-02-26 | -$60.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $149.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $34.82M derived: sum of 2 quarters · filed 2025-11-06 | -$19.33M 10-Q · filed 2025-11-06 | -$87.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$114.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$168.35M 10-Q · filed 2025-08-07 | -$236.18M derived: sum of 3 quarters · filed 2026-02-26 | -$331.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$54.15M 10-Q · filed 2025-05-08 | -$121.97M derived: sum of 2 quarters · filed 2026-02-26 | -$217.38M derived: sum of 3 quarters · filed 2026-02-26 | -$262.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$67.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$163.24M derived: sum of 2 quarters · filed 2026-02-26 | -$208.47M derived: sum of 3 quarters · filed 2026-02-26 | -$140.18M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$95.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$140.65M derived: sum of 2 quarters · filed 2024-11-07 | -$72.35M 10-Q · filed 2024-11-07 | -$98.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$45.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $23.06M 10-Q · filed 2024-08-08 | -$2.76M derived: sum of 3 quarters · filed 2025-02-27 | -$34.01M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $68.30M 10-Q · filed 2024-05-09 | $42.47M derived: sum of 2 quarters · filed 2025-02-27 | $11.22M derived: sum of 3 quarters · filed 2025-02-27 | -$12.74M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$25.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$57.08M derived: sum of 2 quarters · filed 2025-02-27 | -$81.04M derived: sum of 3 quarters · filed 2025-02-27 | $436.72M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$31.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$55.22M derived: sum of 2 quarters · filed 2023-11-07 | $462.55M 10-Q · filed 2023-11-07 | $420.05M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$23.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $493.80M 10-Q · filed 2023-08-03 | $451.30M derived: sum of 3 quarters · filed 2024-02-22 | $424.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $517.76M 10-Q · filed 2023-05-04 | $475.27M derived: sum of 2 quarters · filed 2024-02-22 | $448.76M derived: sum of 3 quarters · filed 2024-02-22 | $439.93M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$42.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$69.01M derived: sum of 2 quarters · filed 2024-02-22 | -$77.83M derived: sum of 3 quarters · filed 2024-02-22 | -$89.30M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$26.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$35.34M derived: sum of 2 quarters · filed 2022-11-03 | -$46.80M 10-Q · filed 2022-11-03 | -$59.21M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$8.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$20.30M 10-Q · filed 2022-08-04 | -$32.70M derived: sum of 3 quarters · filed 2023-02-23 | -$44.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$11.47M 10-Q · filed 2022-05-10 | -$23.87M derived: sum of 2 quarters · filed 2023-02-23 | -$35.90M derived: sum of 3 quarters · filed 2023-02-23 | -$48.11M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$24.43M derived: sum of 2 quarters · filed 2023-02-23 | -$36.65M derived: sum of 3 quarters · filed 2023-02-23 | $286.47M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$12.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$24.24M derived: sum of 2 quarters · filed 2021-11-04 | $298.88M 10-Q · filed 2021-11-04 | $300.29M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$12.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $310.91M 10-Q · filed 2021-08-05 | $312.32M derived: sum of 3 quarters · filed 2022-02-24 | $312.73M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $323.12M 10-Q · filed 2021-05-06 | $324.53M derived: sum of 2 quarters · filed 2022-02-24 | $324.94M derived: sum of 3 quarters · filed 2022-02-24 | $324.99M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.82M derived: sum of 2 quarters · filed 2022-02-24 | $1.87M derived: sum of 3 quarters · filed 2022-02-24 | $2.04M 10-K · filed 2022-02-24 |
| 2019-09-30 | $407.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $458.00K derived: sum of 2 quarters · filed 2020-11-05 | $627.00K 10-Q · filed 2020-11-05 | -$33.05M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $220.00K 10-Q · filed 2020-08-05 | -$33.45M derived: sum of 3 quarters · filed 2021-02-25 | -$66.53M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $169.00K 10-Q · filed 2020-05-07 | -$33.50M derived: sum of 2 quarters · filed 2021-02-25 | -$66.58M derived: sum of 3 quarters · filed 2021-02-25 | -$116.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$33.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$66.75M derived: sum of 2 quarters · filed 2021-02-25 | -$116.81M derived: sum of 3 quarters · filed 2021-02-25 | -$117.20M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$33.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$83.14M derived: sum of 2 quarters · filed 2019-11-06 | -$83.53M 10-Q · filed 2019-11-06 | -$58.97M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$50.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$50.45M 10-Q · filed 2019-08-07 | -$25.90M derived: sum of 3 quarters · filed 2020-02-27 | -$16.59M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$388.00K 10-Q · filed 2019-05-08 | $24.17M derived: sum of 2 quarters · filed 2020-02-27 | $33.48M derived: sum of 3 quarters · filed 2020-02-27 | $33.04M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $24.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $33.86M derived: sum of 2 quarters · filed 2020-02-27 | $33.43M derived: sum of 3 quarters · filed 2020-02-27 | $33.48M 10-K · filed 2020-02-27 |
| 2017-09-30 | $9.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $8.88M derived: sum of 2 quarters · filed 2018-11-08 | $8.93M 10-Q · filed 2018-11-08 | $94.75M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$433.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$383.00K 10-Q · filed 2018-08-08 | $85.44M derived: sum of 3 quarters · filed 2019-02-27 | |
| 2017-03-31 | $50.00K 10-Q · filed 2018-05-09 | $85.88M derived: sum of 2 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $85.83M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $135.56M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | $49.73M 10-Q · filed 2017-11-08 | |||
| 2015-12-31 | $115.99M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |